Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22340453 | 0.84 | CYP1A2 (0.47) | CYP1A2KMT2ASMN1; SMN2POLBGRIN2D | |
| SCHEMBL12205666 | 0.84 | SMN1; SMN2 (0.47) | KMT2ASMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29348746 | 0.82 | KMT2A (0.37) | CYP1A2KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL14051332 | 0.81 | MEN1 (0.44) | KMT2ASMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL8242996 | 0.81 | GRIN2D (0.44) | KMT2ASMN1; SMN2POLBGRIN2DGRIN3B | |
| SCHEMBL1266532 | 0.81 | GRIN2D (0.44) | KMT2ASMN1; SMN2POLBGRIN2DGRIN3B | |
| SCHEMBL1266533 | 0.81 | GRIN2D (0.44) | KMT2ASMN1; SMN2POLBGRIN2DGRIN3B | |
| SCHEMBL10921731 | 0.80 | CHRM5 (0.60) | CYP1A2SMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL15706617 | 0.79 | CYP1A2 (0.44) | CYP1A2KMT2ASMN1; SMN2POLBGRIN2D | |
| SCHEMBL4899005 | 0.79 | ALDH1A1 (0.56) | CYP1A2KMT2ASMN1; SMN2POLBGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919904-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN R & D IRELAND (IE) | 2014-01-08 | — | — | EP | disclosed |
| US-8012939-B2 | Macrocyclic inhibitors of hepatitis C virus | Tibotec Pharmaceuticals Ltd. Co (IE) | 2011-09-06 | — | — | US | disclosed |
| US-8012939-B2 | Macrocyclic inhibitors of hepatitis C virus | Tibotec Pharmaceuticals Ltd. Co (IE) | 2011-09-06 | — | — | US | disclosed |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-11-12 | — | — | US | disclosed |
| WO-2007014921-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CBR1, HCCS, CYP2B6 | CYP1A2 90/4885KMT2A 3866/4885SMN1; SMN2 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.